Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLight Life SciencesBLLSF 16 Equity-to-Asset is 0.81 as of Dec. 2025, which is 10% below its 10-year median of 0.90. GuruFocus rates BLLSF with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, BioLight Life Sciences ranks better than 67.94% on this metric.
BioLight Life Sciences (GREY:BLLSF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioLight Life Sciences Equity-to-Asset Related Terms
BioLight Life Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioLight Life Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLLSF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, BioLight Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLight Life Sciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioLight Life Sciences's Equity-to-Asset falls into.
BioLight Life Sciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioLight Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLight Life Sciences (BLLSF) has a Equity-to-Asset of 0.81 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioLight Life Sciences and its competitors. This is 10% below median its historical median of 0.90. Over the past decade, BioLight Life Sciences' Equity-to-Asset has ranged from 0.25 to 0.95. According to the industry distribution chart, BioLight Life Sciences ranks #454 out of 1416 companies in the Biotechnology industry, placing it in the top 32.1%.
Is BioLight Life Sciences' Equity-to-Asset too high?
BioLight Life Sciences' current Equity-to-Asset of 0.81 is 10% below median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. BioLight Life Sciences' value of 0.81 is 19.1% above this industry median. Based on the distribution chart, BioLight Life Sciences ranks #454 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioLight Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BioLight Life Sciences' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLight Life Sciences ranks #454 out of 1416 companies for Equity-to-Asset. This puts BioLight Life Sciences in the upper half of its industry. The industry median Equity-to-Asset is 0.68. BioLight Life Sciences' value of 0.81 is 19.1% above this benchmark. Historically, BioLight Life Sciences' own Equity-to-Asset has ranged from 0.25 to 0.95 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.68, BioLight Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLight Life Sciences's current Equity-to-Asset of 0.81 is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioLight Life Sciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLight Life Sciences's current Equity-to-Asset is 0.81, which is 10% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLight Life Sciences stock overvalued right now?
BioLight Life Sciences (BLLSF) has a current Equity-to-Asset of 0.81. The current Equity-to-Asset is 0.81, which is 10% below median its 10-year median of 0.90 and 19.1% above the Biotechnology industry median of 0.68. BioLight Life Sciences' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioLight Life Sciences (BLLSF), the current Equity-to-Asset is 0.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
16GF Score
Get the complete analysis for BLLSF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLSF has been successfully added to your 
